A TRPC5 inhibitor (IC50 = 14.7 μM); selective for TRPC5 over TRPC4 and TRPC6 at concentrations up to 100 and 30 μM, respectively; inhibits angiotensin II-induced production of ROS in wild-type podocytes and podocytes expressing a mutant AT1 receptor; suppresses proteinuria as well as reduces pseudocyst formation and podocyte loss in an AT1 receptor transgenic rat model of kidney disease at 50 mg/kg twice per day; decreases the rate of proteinuria and prevents progression in a Dahl salt-sensitive rat model of FSGS